37 related articles for article (PubMed ID: 23393341)
1. Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients.
You JY; Park KH; Lee ES; Kwon Y; Kim KT; Nam S; Kim DH; Bae JW
Cancer Control; 2023; 30():10732748221141672. PubMed ID: 36814068
[TBL] [Abstract][Full Text] [Related]
2. Integrated Multi-Omics Investigations of Metalloproteinases in Colon Cancer: Focus on MMP2 and MMP9.
Buttacavoli M; Di Cara G; Roz E; Pucci-Minafra I; Feo S; Cancemi P
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830271
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.
Maadi H; Soheilifar MH; Choi WS; Moshtaghian A; Wang Z
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298754
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Functional Significant of Heat Shock Proteins (HSPs) in Breast Cancer Unveiled by Multi-Omics Approaches.
Buttacavoli M; Di Cara G; D'Amico C; Geraci F; Pucci-Minafra I; Feo S; Cancemi P
Biology (Basel); 2021 Mar; 10(3):. PubMed ID: 33810095
[TBL] [Abstract][Full Text] [Related]
5. New Synthetic Nitro-Pyrrolomycins as Promising Antibacterial and Anticancer Agents.
Raimondi MV; Presentato A; Li Petri G; Buttacavoli M; Ribaudo A; De Caro V; Alduina R; Cancemi P
Antibiotics (Basel); 2020 May; 9(6):. PubMed ID: 32486200
[No Abstract] [Full Text] [Related]
6. The Role of Matrix Metalloproteinases (MMP-2 and MMP-9) in Ageing and Longevity: Focus on Sicilian Long-Living Individuals (LLIs).
Cancemi P; Aiello A; Accardi G; Caldarella R; Candore G; Caruso C; Ciaccio M; Cristaldi L; Di Gaudio F; Siino V; Vasto S
Mediators Inflamm; 2020; 2020():8635158. PubMed ID: 32454796
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Profiling of Colon Cancer Tissues: Discovery of New Candidate Biomarkers.
Buttacavoli M; Albanese NN; Roz E; Pucci-Minafra I; Feo S; Cancemi P
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32353950
[TBL] [Abstract][Full Text] [Related]
8. Graphene Oxide Carboxymethylcellulose Nanocomposite for Dressing Materials.
Saladino ML; Markowska M; Carmone C; Cancemi P; Alduina R; Presentato A; Scaffaro R; Biały D; Hasiak M; Hreniak D; Wawrzyńska M
Materials (Basel); 2020 Apr; 13(8):. PubMed ID: 32340390
[TBL] [Abstract][Full Text] [Related]
9. Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders.
Coppola A; Cancemi P; Tomasello L; Guarnotta V; Pitrone M; Failla V; Cillino S; Feo S; Pizzolanti G; Giordano C
J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31861546
[TBL] [Abstract][Full Text] [Related]
10. Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors.
Cancemi P; Buttacavoli M; Roz E; Feo S
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416219
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance.
Sisinni L; Pietrafesa M; Lepore S; Maddalena F; Condelli V; Esposito F; Landriscina M
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781465
[TBL] [Abstract][Full Text] [Related]
12. A multiomics analysis of S100 protein family in breast cancer.
Cancemi P; Buttacavoli M; Di Cara G; Albanese NN; Bivona S; Pucci-Minafra I; Feo S
Oncotarget; 2018 Jun; 9(49):29064-29081. PubMed ID: 30018736
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation.
Buttacavoli M; Albanese NN; Di Cara G; Alduina R; Faleri C; Gallo M; Pizzolanti G; Gallo G; Feo S; Baldi F; Cancemi P
Oncotarget; 2018 Feb; 9(11):9685-9705. PubMed ID: 29515763
[TBL] [Abstract][Full Text] [Related]
14. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.
Chong QY; You ML; Pandey V; Banerjee A; Chen YJ; Poh HM; Zhang M; Ma L; Zhu T; Basappa S; Liu L; Lobie PE
Oncotarget; 2017 Sep; 8(43):74188-74208. PubMed ID: 29088778
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Proteomic Screening of 100 Breast Cancer Tissues.
Pucci-Minafra I; Di Cara G; Musso R; Cancemi P; Albanese NN; Roz E; Minafra S
Proteomes; 2017 Jul; 5(3):. PubMed ID: 28686225
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.
Sun Y; Li T; Zhang Y; Zhang Q
Med Sci Monit; 2016 Dec; 22():5035-5040. PubMed ID: 28000658
[TBL] [Abstract][Full Text] [Related]
17. Role of GRP78 in promoting therapeutic-resistant breast cancer.
Cook KL; Clarke R
Future Med Chem; 2015 Aug; 7(12):1529-34. PubMed ID: 26302335
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.
DI Cara G; Marengo G; Albanese NN; Marabeti MR; Musso R; Cancemi P; Pucci-Minafra I
Anticancer Res; 2013 Feb; 33(2):489-503. PubMed ID: 23393341
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
